Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Current Value
$90.811 Year Return
Current Value
$90.811 Year Return
Market Cap
$133.13B
P/E Ratio
74.71
1Y Stock Return
63.29%
1Y Revenue Growth
15.65%
Dividend Yield
0.00%
Price to Book
6.4
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SYK | 58.02% | $148.17B | +32.36% | 0.82% |
ISRG | 51.22% | $191.92B | +72.80% | 0.00% |
EW | 43.20% | $41.40B | +4.84% | 0.00% |
WAB | 39.66% | $33.71B | +69.00% | 0.41% |
RSG | 38.89% | $66.05B | +31.79% | 1.04% |
TT | 37.40% | $92.94B | +82.73% | 0.79% |
COST | 36.60% | $412.13B | +62.81% | 0.49% |
TDG | 36.13% | $70.32B | +35.98% | 0.00% |
XYL | 35.70% | $29.70B | +21.00% | 1.15% |
EQIX | 35.56% | $89.06B | +17.08% | 1.86% |
DVA | 35.40% | $12.87B | +60.92% | 0.00% |
ROL | 33.58% | $23.98B | +23.53% | 1.25% |
ITGR | 33.56% | $4.48B | +49.37% | 0.00% |
BAX | 33.43% | $16.60B | -8.91% | 3.57% |
HLT | 33.25% | $60.89B | +47.04% | 0.24% |
DLR | 33.15% | $62.12B | +37.49% | 2.63% |
ICLR | 32.67% | $16.15B | -27.84% | 0.00% |
WM | 32.10% | $87.92B | +27.58% | 1.34% |
NVO | 32.08% | $342.62B | -0.15% | 1.40% |
LLY | 32.00% | $692.74B | +23.14% | 0.71% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PFBC | <0.01% | $1.24B | +47.28% | 3.02% |
AQB | 0.01% | $3.78M | -37.77% | 0.00% |
FBRT | 0.02% | $1.06B | +0.23% | 10.99% |
HTLD | 0.03% | $962.37M | -5.03% | 0.65% |
HOG | 0.04% | $4.17B | +9.54% | 2.09% |
EPM | -0.06% | $198.21M | +0.68% | 8.19% |
THR | -0.07% | $1.04B | -1.00% | 0.00% |
JWN | -0.08% | $3.72B | +52.15% | 3.40% |
DNOW | -0.08% | $1.52B | +40.10% | 0.00% |
SPWH | 0.08% | $83.65M | -55.71% | 0.00% |
MTUS | 0.09% | $623.82M | -27.79% | 0.00% |
KW | -0.09% | $1.52B | -2.38% | 6.53% |
UFCS | 0.09% | $696.15M | +35.19% | 2.34% |
NUS | 0.11% | $377.31M | -55.82% | 7.56% |
EL | -0.13% | $23.26B | -46.08% | 4.10% |
IMO | -0.15% | $39.72B | +31.84% | 2.23% |
CPRI | -0.15% | $2.36B | -58.95% | 0.00% |
STBA | -0.15% | $1.61B | +49.48% | 3.18% |
BP | 0.17% | $77.24B | -18.61% | 6.32% |
STR | -0.17% | $1.93B | +11.64% | 8.13% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TPST | -29.85% | $37.75M | -77.59% | 0.00% |
LTM | -28.37% | $8.51B | -100.00% | <0.01% |
CLB | -18.06% | $929.61M | +8.55% | 0.20% |
EDSA | -17.54% | $7.11M | -21.79% | 0.00% |
ACRS | -17.47% | $327.87M | +415.67% | 0.00% |
HUSA | -16.99% | $16.69M | -11.56% | 0.00% |
POAI | -15.37% | $4.29M | -78.60% | 0.00% |
WTI | -15.14% | $291.77M | -42.77% | 2.01% |
GSHD | -15.05% | $2.86B | +64.45% | 0.00% |
BALY | -14.41% | $726.31M | +54.50% | 0.00% |
TCS | -13.46% | $14.81M | -84.46% | 0.00% |
NINE | -13.31% | $49.99M | -42.44% | 0.00% |
BPT | -12.79% | $24.61M | -66.18% | 0.00% |
VUZI | -12.33% | $78.77M | -51.69% | 0.00% |
RES | -12.00% | $1.26B | -20.54% | 2.74% |
MNR | -11.90% | $1.66B | -10.71% | 15.90% |
MCRI | -11.55% | $1.52B | +28.67% | 1.45% |
MKTX | -11.11% | $10.10B | +14.58% | 0.83% |
ASIX | -11.00% | $777.60M | +11.37% | 2.18% |
IRBT | -10.86% | $220.33M | -75.58% | 0.00% |
MarketWatch
Boston Scientific Corp. stock outperforms competitors despite losses on the day
Yahoo
We recently published a list of Ken Griffin Stock Portfolio: 10 Stocks to Buy. In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other Ken Griffin’s portfolio stocks to buy. One of Wall Street’s Greatest Ken Griffin, the visionary founder of Citadel Investment Group, launched his hedge […]
Yahoo
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
Yahoo
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Yahoo
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
SeekingAlpha
Fidelity Balanced Fund invests across a mix of stocks and bonds â with a 60%/40% neutral allocation â in seeking income and capital growth.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
WEAT | 0.02% | $120.27M | 0.28% |
CGSM | -0.23% | $514.53M | 0.25% |
FMF | 0.40% | $244.61M | 0.95% |
SPIP | 0.62% | $858.31M | 0.12% |
FLMI | -0.91% | $356.19M | 0.3% |
CGMU | 0.93% | $2.53B | 0.27% |
CCOR | -0.97% | $109.04M | 1.18% |
YEAR | 1.33% | $1.13B | 0.25% |
SMB | 1.63% | $266.77M | 0.07% |
HYD | 1.66% | $3.18B | 0.32% |
FMB | 1.89% | $2.03B | 0.65% |
FTSM | 2.12% | $6.08B | 0.45% |
DBB | 2.14% | $126.37M | 0.77% |
DFNM | 2.23% | $1.40B | 0.17% |
IVOL | 2.35% | $548.70M | 1.02% |
FLDR | 2.42% | $595.01M | 0.15% |
IBD | 2.44% | $330.68M | 0.44% |
CORN | -2.50% | $61.12M | 0.2% |
HYMU | 2.61% | $232.71M | 0.35% |
TDTT | 2.76% | $1.84B | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -30.39% | $195.31M | 0.85% |
TPMN | -28.66% | $40.60M | 0.65% |
TAIL | -25.83% | $67.98M | 0.59% |
CANE | -11.46% | $17.72M | 0.29% |
DBC | -10.21% | $1.39B | 0.87% |
COMT | -10.18% | $829.06M | 0.48% |
USCI | -9.90% | $185.47M | 1.07% |
BCD | -9.81% | $245.02M | 0.3% |
CTA | -9.78% | $350.27M | 0.78% |
SHYD | -9.52% | $311.50M | 0.35% |
CMDY | -9.47% | $279.14M | 0.28% |
FTGC | -9.23% | $2.17B | 1.02% |
EQLS | -8.90% | $76.08M | 1% |
DBE | -8.72% | $50.13M | 0.77% |
USDU | -8.62% | $201.97M | 0.5% |
GSG | -8.45% | $914.42M | 0.75% |
IBHD | -7.99% | $327.80M | 0.35% |
SOYB | -7.73% | $27.32M | 0.22% |
BILZ | -7.71% | $563.02M | 0.14% |
DBO | -7.40% | $217.57M | 0.77% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IHI | 58.78% | $4.91B | 0.4% |
IYH | 47.09% | $3.19B | 0.39% |
XLV | 46.02% | $38.41B | 0.09% |
VHT | 45.64% | $17.06B | 0.1% |
IXJ | 45.50% | $3.89B | 0.41% |
FHLC | 44.47% | $2.73B | 0.084% |
FTC | 41.66% | $1.14B | 0.6% |
QLTY | 41.12% | $1.28B | 0.5% |
JEPI | 40.30% | $36.72B | 0.35% |
TDVG | 40.19% | $841.99M | 0.5% |
PLDR | 40.03% | $676.26M | 0.59% |
FDLO | 39.93% | $1.27B | 0.15% |
QQA | 39.47% | $135.01M | 0% |
USMV | 39.41% | $23.89B | 0.15% |
DVOL | 38.99% | $54.72M | 0.6% |
QUS | 38.93% | $1.43B | 0.15% |
JMOM | 38.54% | $1.22B | 0.12% |
XHE | 38.25% | $213.41M | 0.35% |
BUFR | 38.18% | $5.69B | 0.95% |
TCAF | 38.14% | $2.91B | 0.31% |